• Journal of Haehwa Medicine
• /
• v.20 no.2
• /
• pp.53-65
• /
• 2012

In order to investigate the possibility of SHT as therapeutic for the treatment of atopic dermatitis (AD), cytotoxicity, anti-oxidant activity, modulatory and suppression activities of SHT were tested. 90% or higher cell viability was observed in all tested groups from 25 to 200 ug/ml using Raw 264.7 cells. SHT showed dose-dependent DPPH scavenging activity, with more than 80% scavenging activities at 400 and 800 ug/ml concentrations. SHT showed dose-dependent suppression activity of ROS production, especially at 200 ug/ml of 57.4%. SHT decreased NO production activity dose dependently, expecially at 200 ug/ml of 28.8%. IL-$1{\beta}$, IL-6, MCP-1, TNF-${\alpha}$ production rate were decreased by 45.7%, 15.5%, 8.9%, 16.5% respectively when Raw 264.7 cells were treated with LPS and with SHT of 200 ug/ml. However, only IL-6 and TNF-${\alpha}$ showed significant changes. The results above indicate that SHT significantly reduces the effect of oxidative and inflammatory cytokines. The use of SHT in dermatitis can be widely suggested.

• Journal of Haehwa Medicine
• /
• v.20 no.2
• /
• pp.1-16
• /
• 2012

In order to study the effect of CPS in the treatment of atopic dermatitis (AD), its role on various immune related cytokines were tested. Levels of liver and kidney function markers such as ALT, AST, BUN in NC/Nga mice were all normal indicating no toxicity in CPS treated group. Significant recovery from AD could be observed in CPS treated group through naked eye observation. Dermatitis index was significantly decreased after 11, 12, and 13 weeks of treatment. CD4+, CD8+, CD3+ /CD69+ immune cell ratio in DLN were decreased significantly by 37.2%, 49%, 20.8% in CPS treated group. CD4+ and CD11b+ /Gr-1+ immune cell ratio in dorsal skin were decreased significantly by 50.8% and 59.2% in CPS treated group. Expression of IL-4, IL-5, IL-6, IL-13 and TNF-${\alpha}$ in spleen were decreased by 78.8%, 97.8%, 64.7%, 73.6%, and 68.4%, respectively in CPS treated group. The results above strongly indicated the significant immune modulatory effect of CPS and thus clinical application of CPS on AD treatment.

• Journal of Haehwa Medicine
• /
• v.20 no.2
• /
• pp.41-52
• /
• 2012

In vitro tests were performed using CST to investigate its role on oxidative damages and inflammatory cytokines. 90% or higher cell viability was observed in CST treated groups from 25 to 200 ${\mu}g/m{\ell}$ using Raw 264.7 cells. CST showed dose-dependent DPPH scavenging activity, with 91.3% and 92.2% scavenging activities at 400 and 800 ${\mu}g/m{\ell}$ concentrations, respectively. CST showed dose-dependent suppression activity of ROS production, especially at 200 ${\mu}g/m{\ell}$ of 41.3%. CST decreased NO production activity, with significant decrease of 16.2% and 33.5% at 100 and 200 ${\mu}g/m{\ell}$ concentrations, respectively. IL-$1{\beta}$, IL-6, MCP-1 production rate were significantly decreased by 30.0%, 27.2%, 22.1% when Raw 264.7 cells were treated with LPS and with CST of 200 ${\mu}g/m{\ell}$. Also, TNF-${\alpha}$ production rate was decreased by 28.6%. The results above indicated therapeutic effect of CST on the AD through anti-oxidative and immune modulatory effect. Various blending of drug substances with CST should be clinically tested.

• Journal of Haehwa Medicine
• /
• v.20 no.2
• /
• pp.29-39
• /
• 2012

To investigate the clinical aspects of CHT in atopic dermatitis (AD) treatments, the effect of CHT in anti-oxidative and anti-inflammatory cytokines were tested. 100% or higher cell viability was observed in all tested groups from 25 to 200 ${\mu}g/m{\ell}$ using Raw 264.7 cells. CHT showed dose-dependent DPPH scavenging activity, with more than 90% scavenging activities at 800 ${\mu}g/m{\ell}$ concentrations. CHT showed dose-dependent suppression activity of ROS production, especially at 200 ${\mu}g/m{\ell}$ of 37.5%. CHT decreased NO production activity, with significant decrease of 33.2% at 200 ${\mu}g/m{\ell}$. IL-6, MCP-1, TNF-${\alpha}$ production rate were decreased by approximately 25% when Raw 264.7 cells were treated with LPS and with CHT of 200 ${\mu}g/m{\ell}$. Also, IL-$1{\beta}$ production rate was decreased by 25% at 100 ${\mu}g/m{\ell}$. The results above indicate that CHT significantly reduces the effect of oxidative and inflammatory cytokines. The use of CHT in dermatitis can be widely suggested.

• Journal of Haehwa Medicine
• /
• v.20 no.2
• /
• pp.17-27
• /
• 2012

In order to investigate the possibility of Kamisamultang(KMSMT) as therapeutic for the treatment of atopic dermatitis(AD), cytotoxicity, anti-oxidant activity, modulatory and suppression activities of KMSMT were tested. 90% or higher cell viability was observed in all tested groups from 25 to 200 ${\mu}g/m{\ell}$ using Raw 264.7 cells. KMSMT showed dose-dependent DPPH scavenging activity, with more than 80% scavenging activities at 400 and 800 ${\mu}g/m{\ell}$ concentrations. KMSMT showed dose-dependent suppression activity of reactive oxygen species(ROS) production, especially at 200 ${\mu}g/m{\ell}$ of 42.6%. KMSMT decreased nitric oxide(NO) production activity dose dependently, expecially at 200 ${\mu}g/m{\ell}$ of 30.9%. IL-$1{\beta}$, IL-6, MCP-1, TNF-${\alpha}$ production rate were decreased by 45.7%, 15.5%, 8.9%, 16.5% respectively when Raw 264.7 cells were treated with LPS and with KMSMT of 200 ${\mu}g/m{\ell}$. However, only IL-$1{\beta}$ and MCP-1 showed significant changes. The results above strongly suggest the modulatory and suppressive effect of KMSMT. The results above indicate that KMSMT significantly reduces the effect of oxidative and inflammatory cytokines. The use of KMSMT in atopic dermatitis can be widely suggested.

• Journal of Haehwa Medicine
• /
• v.17 no.2
• /
• pp.137-148
• /
• 2008

In order to investigate the effects of JHG on immune cells in BALF, clinically prescribed JHG was tested using OVA induced asthma animal model. The results are shown below: 1. JHG significantly reduced the total number of cells in BALF compared to that of the control at 400 mg/kg doses. 2. JHG significantly reduced the number of CD3+/CD69+ cells in BALF at 400 and 200 mg/kg doses. 3. JHG significantly reduced the number of CCR3+ cells in BALF at 400 and 200 mg/kg doses. 4. JHG significantly reduced the number of B220+/CD22+ cells in BALF at 400 and 200 mg/kg doses. 5. JHG significantly reduced the number of B220+/IgE+ cells in BALF at 400 and 200 mg/kg doses. 6. JHG significantly reduced the number of B220+/CD45+ cells in BALF at 400 and 200 mg/kg doses. From the results above, anti-asthmatic efficacy of JHG through anti-oxidative activity as well as immune control activity has been experimentally proven. In depth study of JHG on various pathological factors and individual drug contents of JHG should follow.

• Journal of Haehwa Medicine
• /
• v.17 no.2
• /
• pp.51-68
• /
• 2008

The effect of combinational treatment of oral HTGMB and topical CSGMB ("H&C" hereinafter) on the changes of dermal inflammation index and immune system were studied using NC/Nga atopic dermatitis animal model. 1. Through naked eye examination, H&C ameliorated atopic dermatitis compared to the control group. Significant reduction of dermal inflammation index was observed after 12 weeks of treatment. 2. The H&C treated group showed 51% increase in the number of immune cells in DLN, and 59% increase in the number of immune cells is dorsal skin. 3. The H&C treated group showed decrease of 26%, 8%, 59% in CD19+, CD3+/CD69+, B220+/IgE+ cells in DLN respectively. On the other hand, CD3+, CD8+, CD4+ cells were increased by 8%, 31%, 12%, respectively. 4. The H&C treated group showed significant decrease of 38% and 47% in B220+/IgE+, CD11b+/Gr-1+ cells within dorsal skin respectively. Also, a decrease in CCR3+ cells by 21% was observed. 5. Significant decrease of the production of IL-4, IL-5, GM-CSF by 39%, 65%, 60% respectively, in spleen cells activated with CD3 and CD28 were observed in the H&C treated group. The results above strongly suggest significance of anti-atopic dermatitis effect of combinational treatment of oral HTGMB and topical CSGMB through immune modulation. Further applications in clinical use of the treatment are anticipated.

• Journal of Haehwa Medicine
• /
• v.17 no.2
• /
• pp.69-86
• /
• 2008

In order to validate the objective efficacy of CBPT on anti-asthma and to develop effective therapeutics for asthma treatments, immunological modulatory mechanism was studied using animal model using OVA-Alum. The results are listed below. When treated with CBPT, survival rate of hFCs at 250 ug/ml was above 90%. AST and ALT, indicators of liver function measurements were in the normal range. Compared to the control group, CBPT treated group showed significant reduction in liver weights at both 400 and 200 mg/kg, and significant decrease of total liver cells at 400 mg/kg. Significant increase in CD4+ and CD8+ cells in DLN was observed in the CBPT treated group. Slight increase in CD3+, CD4+/CD25+ cells were also observed. On the other hand, CBPT significantly reduced the CD3+/CD69+ cell numbers at both concentrations. Slight decrease of CD19+ cells was also observed. CBPT significantly reduced the CD3e+/CD69+, CCR3+ and CD11b+/Gr-1+ cells in lung tissues at both doses. However, significant decrease of CD3e+ and B220+/IgE+ cells was only observed at 400 mg/kg dosed group. The results above strongly suggest the anti-asthmatic effect of CBPT through immunological modulation. By using various concentrations of CBPT, broader clinical applications of CBPT on anti-asthmatic treatment can be developed. The EBM database should provide valuable information in the development of drugs for asthma treatments.

• Journal of Haehwa Medicine
• /
• v.17 no.2
• /
• pp.87-99
• /
• 2008

To investigate the effects of ESWTT on rheumatoid arthritis in collagen-induced arthritis mice model, the animals were orally administrated with the extract following by analyzing the changes of lymphocyte composition in spleen with flow cytometry. These results suggest as follows; 1. ESWTT decreased the total cell number of spleen at 400 and 200 mg/kg about 41% and 32%, respectively. 2. ESWTT reduced the number of CD19+ cells in spleen at 400 and 200 mg/kg about 51% and 46%, respectively. 3. ESWTT down-regulated the number spleen CD3+ cells approximately 26% at 400 mg/kg-treated group. 4. ESWTT decreased the number of CD3+/CD69+ cells in spleen at 400 and 200 mg/kg about 79% and 76%, respectively. 5. ESWTT reduced the number of CD4+ and CD8+ cells in spleen, however, the results were not significant. 6. ESWTT decreased the number of CD4+/CD25+ cells in spleen at 400 and 200 mg/kg about 60% and 56%, respectively. Taken together these results, ESWTT has an efficacy on rheumatoid arthritis through inhibiting the proliferation of lymphocytes such as B and T cells.

• KIISE Transactions on Computing Practices
• /
• v.21 no.1
• /
• pp.46-51
• /
• 2015

The explosive growth of data and the rapidly changing technical social evolution new analysis paradigm for predicting and reacting the future the past and present ig data. Prescriptive analysis has a fundamental difference because can support specific behaviors and results according to user's goals with defin researchers establish judgments and activities achiev the goals. However research methods not widely implemented and even the terminology, Prescriptive analysis, is still unfamiliar. This paper thus propose an infrastructure in the prescriptive analysis field with key considerations for enhancing capability of researchers through a case study based on InSciTe Advisory developed with scientific big data. InSciTe Advisory system s developed in 2013, and offers a prescriptive analytics report which contains various As-Is analysis results and To-Be analysis results 5W1H methodology. InSciTe Advisory therefore shows possibility strategy aims to reach a target role model group. Through the availability and reliability of the measurement model the evaluation results obtained relative advantage of 118.8% compared to Elsevier SciVal.